OncoMatch/Clinical Trials/NCT06409390
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
Is NCT06409390 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for metastatic breast cancer.
Treatment: Taxotere · Cytoxan · Trastuzumab deruxtecan · Sacituzumab govitecan · Xeloda · Fulvestrant · Ribociclib · Abemaciclib — The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 hormone receptor positive
hormone positive HER2 negative metastatic breast cancer
Required: HER2 (ERBB2) HER2 negative
hormone positive HER2 negative metastatic breast cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: endocrine therapy (aromatase inhibitor, tamoxifen)
Hormone positive MBC previously treated with endocrine therapy with either an aromatase inhibitor or Tamoxifen (alone or in combination with a CDK4/6 inhibitor).
Cannot have received: (fulvestrant)
Have previously received Fulvestrant for treatment of their breast cancer.
Lab requirements
Blood counts
adequate organ and marrow function as defined in the protocol
Kidney function
adequate organ and marrow function as defined in the protocol
Liver function
adequate organ and marrow function as defined in the protocol
Participants must have adequate organ and marrow function as defined in the protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06409390 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 hormone receptor positive is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 HER2 negative is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages